zolmitriptan

[zōl″mĭ-trip´tan] a selective serotonin receptor agonist used to relieve acute migraine, administered orally.

zolmitriptan

Zomig Rapimelt (CA) (UK), Zomig-ZMT

Pharmacologic class: Selective 5-hydroxytryptamine receptor agonist

Therapeutic class: Antimigraine agent

Pregnancy risk category C

Action

Blocks serotonin release, constricting inflamed and dilated cerebral and cranial blood vessels and reducing nerve transmission in trigeminal pain pathways

Availability

Nasal spray: 5-mg single-use spray device

Tablets (immediate-release): 2.5 mg, 5 mg

Tablets (orally disintegrating): 2.5 mg

Indications and dosages

➣ Acute migraine

Adults: 1.25 to 2.5 mg (immediate-release) P.O., repeated if migraine returns in 2 hours or less; maximum dosage is 10 mg in any 24-hour period. Or 2.5 mg (orally disintegrating tablet) P.O., repeated if migraine returns in 2 hours or less; maximum dosage is 10 mg in any 24-hour period. Alternatively, one dose of nasal spray (5 mg); if migraine returns, may repeat dose after 2 hours; don't exceed maximum daily dosage of 10 mg in any 24-hour period.

Dosage adjustment

• Hepatic impairment

Contraindications

• Hypersensitivity to drug

• Hemiplegic or basilar migraine

• Ischemic cardiac disease or other significant cardiac disease

• Uncontrolled hypertension

• Cerebrovascular accident or transient ischemic attack

• Peripheral vascular disease, including ischemic bowel disease

• Use of ergot-type or ergot-containing drugs or other 5-HT₁ agonists within past 24 hours

• MAO inhibitor use within past 14 days

Precautions

Use cautiously in:

• hepatic or renal impairment

• risk factors for coronary artery disease (such as strong family history of this disease, diabetes mellitus, obesity, cigarette smoking, high cholesterol level, men older than age 40, postmenopausal women)

• elderly patients

• pregnant or breastfeeding patients

• children.

Administration

• Place orally disintegrating tablet on patient's tongue, where it should dissolve.

• Don't break orally disintegrating tablet in half.

• Know that each nasal spray unit is intended for one use only.

Adverse reactions

CNS: paresthesia, asthenia, dizziness, insomnia, hyperesthesia, drowsiness, syncope, vertigo, agitation, depression, anxiety, emotional lability, fatigue, malaise

CV: chest pain, heaviness, or tightness; hypertension; palpitations; angina; arrhythmias

EENT: dry eyes, ear pain, tinnitus, epistaxis, altered sense of smell, laryngitis

GI: nausea, vomiting, dyspepsia, dysphagia, gastroenteritis, esophagitis, dry mouth

GU: urinary frequency, hematuria, polyuria, cystitis

Hepatic: hepatic dysfunction

Metabolic: hyperglycemia

Musculoskeletal: leg cramps, neck pain, tenosynovitis, myasthenia, myalgia, back pain

Respiratory: bronchitis, hiccups

Skin: pruritus, rash, diaphoresis, bruising, urticaria, photosensitivity

Other: unusual taste, flushing, sweating or redness in face (with nasal spray); fever; chills; excessive thirst; facial or tongue edema; pressure or tightness in throat or jaw; yawning; warm or cold sensation

Interactions

Drug-drug. Cimetidine: doubling of zolmitriptan's half-life

Ergot-containing drugs: vasospasm

Fluoxetine, fluvoxamine, paroxetine, sertraline: weakness, incoordination, hyperreflexia

MAO inhibitors: increased zolmitriptan effects

Drug-diagnostic tests. Blood glucose: increased level

Drug-herbs. S-adenosylmethionine (SAM-e), St. John's wort: serotonin syndrome

Drug-behaviors. Smoking: increased risk of adverse cardiovascular effects

Patient monitoring

• Assess therapeutic response to help gauge drug efficacy.

• Watch for adverse cardiovascular and respiratory reactions, particularly dyspnea and chest pain or tightness.

• Assess blood glucose level in diabetic patient.

Patient teaching

See Tell patient to immediately report shortness of breath or pain or tightness in chest or throat.

• Explain that drug is intended to treat migraine, not prevent it.

• Tell patient to remove orally disintegrating tablet from blister pack just before taking it, and then place it on his tongue and let it dissolve. Instruct him not to break it.

• Teach patient proper use of nasal spray. Tell him each unit is intended for one use only.

• Caution patient to avoid driving and other hazardous activities during severe migraine or if drug causes adverse CNS effects.

• Inform patient that smoking may increase drug's cardiovascular risks.

• Advise female of childbearing age not to take drug if she is, might be, or plans to become pregnant.

• Advise patient to avoid sun exposure and to wear sunscreen and protective clothing when going outdoors.

• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, herbs, and behaviors mentioned above.

zolmitriptan

(zŏl′mĭ-trĭp′tn)n. A drug that acts as a serotonin receptor agonist and is used to treat migraine headaches.

zolmitriptan

Zomig^™ Neurology A selective 5-HT_1B/1D agonist for acute migraine with/without aura, effective in ±²⁄₃ of Pts within 1 hr of therapy Adverse effects Paresthesia, anesthesia, head & neck pain/tightness/pressure, dizziness Contraindications ASHD, CAD, HTN, MI

zolmitriptan

A drug that stimulates SEROTONIN receptors and is used to treat MIGRAINE. A brand name is Zomig.

单词	zolmitriptan
释义	zolmitriptan zol·mi·trip·tan Z0021725 (zŏl′mĭ-trĭp′tn)n. A drug that acts as a serotonin receptor agonist and is used to treat migraine headaches. [(a)zol(e) + (a)mi(no) + -triptan, triptan suffix; see triptan.] Translations zolmitriptan zolmitriptan [zōl″mĭ-trip´tan] a selective serotonin receptor agonist used to relieve acute migraine, administered orally. zolmitriptan Zomig Rapimelt (CA) (UK), Zomig-ZMT *Pharmacologic class:* Selective 5-hydroxytryptamine receptor agonist *Therapeutic class:* Antimigraine agent *Pregnancy risk category C* Action Blocks serotonin release, constricting inflamed and dilated cerebral and cranial blood vessels and reducing nerve transmission in trigeminal pain pathways Availability Nasal spray: 5-mg single-use spray device Tablets (immediate-release): 2.5 mg, 5 mg Tablets (orally disintegrating): 2.5 mg Indications and dosages ➣ Acute migraine Adults: 1.25 to 2.5 mg (immediate-release) P.O., repeated if migraine returns in 2 hours or less; maximum dosage is 10 mg in any 24-hour period. Or 2.5 mg (orally disintegrating tablet) P.O., repeated if migraine returns in 2 hours or less; maximum dosage is 10 mg in any 24-hour period. Alternatively, one dose of nasal spray (5 mg); if migraine returns, may repeat dose after 2 hours; don't exceed maximum daily dosage of 10 mg in any 24-hour period. Dosage adjustment • Hepatic impairment Contraindications • Hypersensitivity to drug • Hemiplegic or basilar migraine • Ischemic cardiac disease or other significant cardiac disease • Uncontrolled hypertension • Cerebrovascular accident or transient ischemic attack • Peripheral vascular disease, including ischemic bowel disease • Use of ergot-type or ergot-containing drugs or other 5-HT₁ agonists within past 24 hours • MAO inhibitor use within past 14 days Precautions Use cautiously in: • hepatic or renal impairment • risk factors for coronary artery disease (such as strong family history of this disease, diabetes mellitus, obesity, cigarette smoking, high cholesterol level, men older than age 40, postmenopausal women) • elderly patients • pregnant or breastfeeding patients • children. Administration • Place orally disintegrating tablet on patient's tongue, where it should dissolve. • Don't break orally disintegrating tablet in half. • Know that each nasal spray unit is intended for one use only. Adverse reactions CNS: paresthesia, asthenia, dizziness, insomnia, hyperesthesia, drowsiness, syncope, vertigo, agitation, depression, anxiety, emotional lability, fatigue, malaise CV: chest pain, heaviness, or tightness; hypertension; palpitations; angina; arrhythmias EENT: dry eyes, ear pain, tinnitus, epistaxis, altered sense of smell, laryngitis GI: nausea, vomiting, dyspepsia, dysphagia, gastroenteritis, esophagitis, dry mouth GU: urinary frequency, hematuria, polyuria, cystitis Hepatic: hepatic dysfunction Metabolic: hyperglycemia Musculoskeletal: leg cramps, neck pain, tenosynovitis, myasthenia, myalgia, back pain Respiratory: bronchitis, hiccups Skin: pruritus, rash, diaphoresis, bruising, urticaria, photosensitivity Other: unusual taste, flushing, sweating or redness in face (with nasal spray); fever; chills; excessive thirst; facial or tongue edema; pressure or tightness in throat or jaw; yawning; warm or cold sensation Interactions Drug-drug. Cimetidine: doubling of zolmitriptan's half-life Ergot-containing drugs: vasospasm Fluoxetine, fluvoxamine, paroxetine, sertraline: weakness, incoordination, hyperreflexia MAO inhibitors: increased zolmitriptan effects Drug-diagnostic tests. Blood glucose: increased level Drug-herbs. S-adenosylmethionine (SAM-e), St. John's wort: serotonin syndrome Drug-behaviors. Smoking: increased risk of adverse cardiovascular effects Patient monitoring • Assess therapeutic response to help gauge drug efficacy. • Watch for adverse cardiovascular and respiratory reactions, particularly dyspnea and chest pain or tightness. • Assess blood glucose level in diabetic patient. Patient teaching See Tell patient to immediately report shortness of breath or pain or tightness in chest or throat. • Explain that drug is intended to treat migraine, not prevent it. • Tell patient to remove orally disintegrating tablet from blister pack just before taking it, and then place it on his tongue and let it dissolve. Instruct him not to break it. • Teach patient proper use of nasal spray. Tell him each unit is intended for one use only. • Caution patient to avoid driving and other hazardous activities during severe migraine or if drug causes adverse CNS effects. • Inform patient that smoking may increase drug's cardiovascular risks. • Advise female of childbearing age not to take drug if she is, might be, or plans to become pregnant. • Advise patient to avoid sun exposure and to wear sunscreen and protective clothing when going outdoors. • As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, herbs, and behaviors mentioned above. zolmitriptan (zŏl′mĭ-trĭp′tn)n. A drug that acts as a serotonin receptor agonist and is used to treat migraine headaches. zolmitriptan Zomig^™ Neurology A selective 5-HT_1B/1D agonist for acute migraine with/without aura, effective in ±²⁄₃ of Pts within 1 hr of therapy Adverse effects Paresthesia, anesthesia, head & neck pain/tightness/pressure, dizziness Contraindications ASHD, CAD, HTN, MI zolmitriptan A drug that stimulates SEROTONIN receptors and is used to treat MIGRAINE. A brand name is Zomig. AcronymsSeeZMT
随便看	electronic microscope electronic military personnel office electronic military personnel records system electronic missile acquisition electronic missile maintenance officer electronic mobile exchange electronic mockup electronic modular control panel electronic modular test rig electronic module electronic module assembly electronic module test console electronic molding corporation electronic money electronic money institution electronic money system security objectives electronic money transfer electronic monitoring electronic monitoring device ebcsd ebcsg ebct ebcta ebctc ebctcg

zolmitriptan

zol·mi·trip·tan

zolmitriptan

zolmitriptan

zolmitriptan

Action

Availability

Indications and dosages

Dosage adjustment

Contraindications

Precautions

Administration

Adverse reactions

Interactions

Patient monitoring

Patient teaching

zolmitriptan

zolmitriptan

zolmitriptan